This segment focuses on the research, development, manufacturing, and commercialization of blood products. Key activities include the production of intravenous immunoglobulin, human albumin, and other blood-derived therapeutics. Research and development efforts are focused on improving the efficacy and safety of existing products, as well as developing new blood products to treat a wider range of conditions. The company utilizes advanced technologies in plasma fractionation and purification to ensure product quality and safety. These products are used in various therapeutic areas, including immunology, hematology, and critical care, addressing conditions such as immune deficiencies, bleeding disorders, and shock. Tiantan Bio's market positioning is strong in China, with a focus on providing high-quality, affordable blood products. Future opportunities include expanding product offerings and exploring international markets. Regulatory compliance and clinical trials are critical aspects of this segment, ensuring product safety and efficacy. Partnerships with plasma collection centers and hospitals are essential for supply and distribution.

This segment is dedicated to the research, development, and production of vaccines, primarily for infectious diseases. The company focuses on developing vaccines for diseases prevalent in China and globally. Research and development activities include the development of new vaccine formulations, exploring innovative technologies like mRNA vaccines, and conducting clinical trials to assess safety and efficacy. The company utilizes advanced technologies in vaccine production, including cell culture and purification techniques. The therapeutic areas covered include infectious diseases, with a focus on preventing diseases such as hepatitis B and other viral infections. The patient impact is significant, as vaccines help prevent disease and reduce healthcare costs. Tiantan Bio aims to be a leading vaccine provider in China, with a focus on quality and affordability. Future opportunities include expanding the vaccine portfolio and exploring partnerships for global distribution. Regulatory approvals and clinical trial data are crucial for market access and product validation. Collaborations with research institutions and government agencies are essential for vaccine development and deployment.